Biovitrum's Interim Report January to September 2006.STOCKHOLM, Sweden -- Biovitrum (STO:BVT BVT Bouvet Island (ISO Country code) BVT Brevet BVT Bournville Village Trust (UK) BVT Build Verification Test (Software testing process) ): Strong Trend Continues in Q3 January - September * Net revenues for the period increased by 69 percent to SEK SEK In currencies, this is the abbreviation for the Swedish Krona. Notes: The currency market, also known as the Foreign Exchange market, is the largest financial market in the world, with a daily average volume of over US $1 trillion. 956.3 M (567.3) * Net profit for the period amounted to SEK 99.0 M (-54.0) and earnings per share amounted to SEK 2.1 (-1.0) * Cash and cash equivalents and short-term investments amounted to SEK 929.4 M (1,021.4) on September 30 July - September * Net revenues for the third quarter increased by 19 percent to SEK 248.2 M (209.4) * Net profit for the quarter amounted to SEK 5.6 M (-4.0) and earnings per share amounted to SEK 0.1 (-0.1) * Biovitrum was listed on the Stockholm Stock Exchange The Stockholm Stock Exchange (Swedish: Stockholmsbörsen) is a stock exchange located in Stockholm, Sweden. Founded in 1863 [1] it is the primary securities exchange of the Nordic Countries. on September 15 * Phase I study initiated within the 5-HT6 project for the treatment of obesity * Phase IIa study initiated within the 5-HT2A project for the treatment of glaucoma glaucoma (glôkō`mə), ocular disorder characterized by pressure within the eyeball caused by an excessive amount of aqueous humor (the fluid substance filling the eyeball). "During our first period as a public company we continued to enjoy the strong trend of increasing revenues and positive development in our project portfolio," says Mats Pettersson, CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Biovitrum. "Our position as an integrated biopharma company with stable finances and a broad project portfolio provides us with a solid platform for the future. I would also like to take this opportunity to express my gratitude for all of the interest and appreciation we have met in connection with our IPO (Initial Public Offering) The first time a company offers shares of stock to the public. While not a computer term per se, many founders, employees and insiders of computer companies have found this acronym more exciting than any tech term they ever heard. and to welcome all of our new shareholders." About Biovitrum Biovitrum is one of the largest biopharma companies in Europe. With operations in Sweden and in the UK Biovitrum conducts research and develops pharmaceuticals for unmet medical needs both for common diseases and conditions that affect smaller patient populations. Biovitrum has a broad and balanced R&D portfolio with several projects in clinical and preclinical phases for the treatment of obesity, diabetes, inflammation and eye and blood diseases as well as a number of well defined niche indications. Biovitrum develops and produces protein-based drugs on a contractual basis and markets a range of specialist pharmaceuticals primarily in the Nordic countries. Biovitrum has approximately revenues of USD USD In currencies, this is the abbreviation for the U.S. Dollar. Notes: The currency market, also known as the Foreign Exchange market, is the largest financial market in the world, with a daily average volume of over US $1 trillion. 119 million and 550 employees. Biovitrum is listed on the Stockholm Stock Exchange since September 15, 2006. For more information see www.biovitrum.com/. This information was brought to you by Waymaker http://www.waymaker.net |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion